KMT2A and leukemia: BET inhibitors, such as JQ1 and OTX015 (MK-8628) showed efficacy in cell lines, mouse models and ex vivo patient samples of MLL-fused, NPM1-, FLT3-, or IDH2-mutated leukemias [148].